The Regulator
States have until December 11 to decide whether to shield Medicaid enrollees from work-requirement coverage losses for six more months, and Nebraska has already said no. The Centers for Medicare & Medicaid Services (CMS) sent state Medicaid directors a letter, “Optional Hold Harmless Period for Community Engagement Implementation,” dated November 13. The work requirement itself starts January 1, 2027 in 43 states plus the District of Columbia, and CMS says it cannot move that statutory date. The new option lets a state, through June 30, 2027, stop short of denying applications or disenrolling people solely because they did not show compliance. States that opt in must still check whether each person meets the requirement or qualifies for an exemption or hardship exception, and the option does not touch income or age rules. The development of the last 48 hours: a Nebraska spokesperson said the state sees “no need” to participate, per a November 18 Nebraska Examiner report relayed by the Healthcare Financial Management Association (HFMA), and West Virginia is undecided. As of HFMA’s November 19 update, no state was reported as having formally opted in. Who it hits: Medicaid expansion adults subject to the requirement, state Medicaid agencies building eligibility systems, and the managed-care plans and hospitals whose revenue follows enrollment. Confidence: High on the letter’s existence and title; Med on the terms and the December 11 date, which come from HFMA and Healthcare Dive reporting because we could not read the letter’s body text; Low on Nebraska’s position, which we have not confirmed with the state. Sources: CMS State Medicaid Director letter (SMD 26-006). Supplemental: HFMA, Healthcare Dive.
UPDATE on the Senate vote we covered November 17: there was no vote, because the White House pulled Heidi Overton’s nomination to lead the Food and Drug Administration (FDA). The Senate Health, Education, Labor and Pensions (HELP) Committee’s November 18 executive session page lists three other nominees and no FDA commissioner. BioPharma Dive reports that Committee Chair Bill Cassidy confirmed the withdrawal at the session and said “confirming a permanent FDA commissioner appears to fall to Senate Democrats.” Kyle Diamantas, the deputy commissioner for food, stays acting commissioner. Who it hits: drug and device makers waiting on a permanent FDA leader, with the next pick likely months away. Reuters sources say Sen. Roger Marshall is under consideration, which is unconfirmed. Confidence: High that the nomination was not on the agenda; Med on the withdrawal, which rests on press reports and no White House statement we could find; Low on any successor. Sources: Senate HELP Committee, November 18 executive session. Supplemental: BioPharma Dive, Pharmaceutical Commerce, citing Reuters.
InnovAge, a Program of All-Inclusive Care for the Elderly (PACE) operator, agreed to pay $36 million to resolve False Claims Act allegations that it failed to provide required medical services and timely specialist referrals. The Office of Inspector General’s (OIG) enforcement feed lists the November 17 Department of Justice settlement with Denver-based InnovAge Holding Corporation. PACE plans take a fixed payment to run all of a frail senior’s care, so skipped services and slow referrals are the cost-saving the government says it is paying for. The same feed lists a separate $5.7 million Colorado Medicaid settlement with InnovAge that day. Who it hits: PACE operators and their medical directors, whose referral timeliness is now an enforcement target. Confidence: Med. The OIG listing gives the amount and allegations but not the covered period; the Justice Department’s own release was not reachable this run. Sources: OIG enforcement action, InnovAge $36 million settlement.
Doctors have 41 days left on the telehealth prescribing flexibilities for controlled substances, and the permanent rule is still not final. The Drug Enforcement Administration (DEA) and HHS extended the pandemic-era flexibilities through December 31, 2026, letting registered practitioners prescribe Schedule II to V drugs by telemedicine without a prior in-person visit. DEA’s own regulatory agenda lists the permanent “Special Registrations for Telemedicine” final rule at the final stage, with action projected for November 2026, and says the agency is still reviewing more than 6,400 comments on its January 2025 proposal and “considering various alternatives.” Who it hits: telehealth platforms, behavioral health and addiction practices, and any clinician prescribing stimulants or buprenorphine remotely. Confidence: High on the December 31 expiration; Med on timing, since the agenda is a projection and its page carries no as-of date. Sources: Federal Register, Fourth Temporary Extension, 90 FR 61301, Unified Agenda entry, RIN 1117-AB40.
FDA published two guidance notices today: a final guidance on transferring a device clearance and draft generic-drug study recommendations open for comment until January 19, 2027. The final guidance answers common questions about transferring or selling a 510(k) clearance, the premarket notification that lets a device reach market, from one holder to another. The second notice adds draft and revised draft product-specific guidances on designing the bioequivalence studies that support generic drug applications, docket FDA-2007-D-0369. Who it hits: device makers doing acquisitions or asset sales, and generic drug developers planning studies. Confidence: High on the dates and dockets; we summarize the Federal Register abstracts, not the full guidance text. Sources: Federal Register, 510(k) transfer final guidance (2026-23668), Federal Register, product-specific guidances (2026-23692).
Two prison sentences and a new Montana task force headline this week’s fraud feed. OIG’s enforcement feed lists a Michigan home health agency owner sentenced November 19 to 4 years for a $1.6 million Medicare scheme fueled by illegal kickbacks, and a pharmacy owner sentenced November 18 to 82 months for a $5.6 million health care fraud scheme tied to illegal oxycodone distribution. Also November 19, federal, state and local officials held the inaugural meeting of Montana’s Fraud Task Force in Helena, convened with the U.S. Attorney’s Office for the District of Montana, to share information and coordinate investigations. No dollar figures were posted for the task force. Who it hits: home health agencies and pharmacies in the sentenced cases’ markets and Montana providers now under a dedicated coordination body. Confidence: Med. We rely on OIG’s listings; the underlying Justice Department releases were not reviewed. Sources: OIG, Michigan home health owner sentenced, OIG, pharmacy owner sentenced, OIG, Montana Fraud Task Force.
Free. One email a day at 6pm your time, or one summary every Friday. Switch or stop anytime.